<div id="readability-page-1"><div>         <div>                        <p>,  /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in <i>Nature Communications</i>, reporting that Efsubaglutide Alfa, a long-acting <span>GLP-1</span> receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin, while also demonstrating favorable β-cell functional responses.</p>             <p><span>                 Continue Reading                   <br/>                   <i></i>                                </span>             </p>             <div>               <div>                 <div>                                       <div>                                                               <figure>                        <p><img id="imageid_2" src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/>                    </p>                       <figcaption>                </figcaption>     </figure>                                                                                  </div>                 </div>               </div>             </div>             <p>The study was led by Academician Weiping Jia and co-corresponded by Professor Qinghua Wang, Distinguished Professor of Fudan University, Founder of Innogen Pharmaceuticals, and inventor of Efsubaglutide Alfa. The publication marks another important milestone in the clinical development of Efsubaglutide Alfa and provides further mechanistic insights into its therapeutic value beyond glucose lowering.</p>                            <p>SUPER 2 was a randomized, double-blind, placebo-controlled, two-stage adaptive phase IIb/III trial evaluating Efsubaglutide Alfa as add-on therapy to metformin in patients with type 2 diabetes. The results showed that Efsubaglutide Alfa significantly improved HbA1c and other key glycaemic measures, with an overall safety profile consistent with the <span>GLP-1</span> receptor agonist class, with mainly mild-to-moderate gastrointestinal adverse events.</p>               <p>Importantly, the study went beyond conventional efficacy endpoints and further examined β-cell functional responses using mixed-meal tolerance testing and related metabolic indices. Treatment with Efsubaglutide Alfa was associated with improved postprandial insulin and C-peptide responses, improvement in β-cell function-related parameters, and favorable changes in indices reflecting the integrated relationship between insulin secretion and insulin sensitivity. These findings suggest that the clinical benefit of Efsubaglutide Alfa may extend beyond glycaemic control to partial improvement of the underlying pathophysiology of type 2 diabetes.</p><p>This mechanistic signal is particularly meaningful in light of the team's earlier Diabetes Remission study, published in <i>Advances in Therapy</i>, which showed that Efsubaglutide Alfa treatment in drug-naïve patients with type 2 diabetes was associated with remission in a proportion of patients after treatment withdrawal. The SUPER 2 data now provide larger-scale clinical support for the concept that improvement in β-cell function may contribute to the longer-term disease-modifying potential of Efsubaglutide Alfa.</p><p>Innogen Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the discovery, development, and translation of novel therapies for diabetes and other metabolic diseases. The publication of SUPER 2 in <i>Nature Communications</i> not only strengthens the clinical evidence base for Efsubaglutide Alfa, but also highlights the value of integrating mechanistic science, clinical development, and translational medicine to advance next-generation therapies for metabolic diseases.</p><p>SOURCE Innogen Pharmaceuticals</p><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041ODM2NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIyMzQ2UFJfTkVXU19VU1BSX19fX19DTjU4MzY1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041ODM2NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIyMzQ2UFJfTkVXU19VU1BSX19fX19DTjU4MzY1"/></p></div>       </div></div>

159849

520880

<p>A new clinical study published in Nature Communications highlights the effects of Efsubaglutide Alfa, a GLP-1 receptor agonist, on glycaemic control and β-cell function in adults with type 2 diabetes inadequately controlled on metformin. The SUPER 2 trial demonstrated significant improvements in HbA1c and other glycaemic measures, with a safety profile consistent with the GLP-1 class. The findings suggest that Efsubaglutide Alfa may also improve β-cell function, indicating potential long-term benefits beyond glycaemic control. Innogen Pharmaceuticals led the study, emphasizing the importance of mechanistic insights in developing therapies for metabolic diseases.</p>

prnewswire

VanEck Biotech ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

SPDR S&P Biotech

ICBCCS SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

VG Health

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

BlackRock, Inc.

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

iShares Global Healthcare

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

China Southern Hang Seng Biotech ETF(QDII)

iShares Biotechnology ETF

Bosera Hang Seng Health Care ETF(QDII)

Ark Genomic Revolution ETF

Yinhua CSI Innovative Drugs Industry ETF

Health Care Select Sector SPDR

INNOGEN-B

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function